Current Projects

Below you will find a sample of our current in-licensing or out-licensing projects. For further information, please contact us at info@lacertabio.com.

doctor showing

Problem Solved: Novel mTOR 1/2 Inhibitor Available for Licensing

Our client has a Preclinical, highly selective mTOR 1/2 inhibitor available for licensing. This compound is a truly selective inhibitor of both mTORC1 and mTORC2, without PI3K activity or toxicity. With an excellent projected safety profile & oral administration, a number of indications within and outside oncology are possible. For more information, contact us via email by clicking on the link…
Man Receiving IV

Seeking Blood Cancer Clinical Failures

Our client is seeking clinical stage assets in development for any number of blood cancers (AML, CML, etc.).

Our client is especially interested in candidates which have failed in clinical studies, either for safety or efficacy reasons.

Our client has technologies and expertise which they believe can be applied to identify new indications or patient populations, thereby rescuing the clinical and commercial value of these candidates.

Phase III Non-Opioid for Severe Pain

Our client has developed a novel, low-dose formulation of CBD and THC for the treatment of severe cancer pain. 

Our client has clinical data demonstrating significant pain relief in severe cancer pain even with the co-administration of opioids. 

In addition, our client has data demonstrating reduced opioid use while using this product candidate. 

Click on the link below to learn more.